NCT06427941 2026-04-17
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
BeOne Medicines
Phase 1 Recruiting
BeOne Medicines
BeOne Medicines
BeOne Medicines
BeOne Medicines
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NYU Langone Health
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
SillaJen, Inc.
University of Southern California